# Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

> **NCT02157935** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2026 (actual)

## Conditions studied

- COPD Patients

## Interventions

- **DRUG:** Symbicort
- **DRUG:** Formoterol turbohaler
- **OTHER:** Placebo for Symbicort pMDI
- **OTHER:** Placebo for Formoterol Turbohaler

## Key facts

- **NCT ID:** NCT02157935
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-27
- **Primary completion:** 2016-02-08
- **Final completion:** 2016-02-08
- **Target enrollment:** 2026 (ACTUAL)
- **Last updated:** 2017-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02157935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02157935, "Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02157935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*